Last update: July 6, 2018
Minimal risk for breastfeeding and infant.
Quinapril, via its active metabolite, quinaprilat, is an angiotensin converting enzyme inhibitor (ACEI) used in the treatment of high blood pressure and heart failure.
Oral administration every 12-24 hours.
It is excreted in breastmilk in clinically insignificant amounts (Anderson 2018, Begg 2001).
No problems have been observed in infants whose mothers were taking other ACEIs (Anderson 2018).
Due to its possible renal toxicity in preterm infants, it is preferable to avoid its use during the neonatal period in case of prematurity. (Serrano 2015).
The protective role of breastfeeding against maternal hypertension has been proven (Park 2018).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM